TMO stock forecast, quote, news & analysis

Key Takeaways

• Thermo Fisher Scientific shares surged approximately 14.6% in the last 30 days, climbing from $464.61 on June 18 to $532.48 as of the July 17 close.
• The rally was fueled by broad institutional buying, upbeat Q2 earnings expectations, and a series of strategic product launches and partnerships.
• Over the full quarter, TMO posted a modest gain of about 1.1%, masking a sharp V-shaped recovery from mid-May lows near $438.
• Wall Street maintains a consensus Moderate Buy rating with an average price target of $602.14, implying further upside from current levels.
• Q2 2026 earnings are scheduled for July 23, with analysts projecting EPS of $5.71 on revenue of $11.68 billion.
• Institutional ownership remains exceptionally high at 89.23%, underscoring sustained confidence among large investors.

Thermo Fisher Scientific (TMO) Company Overview and Market Position

Thermo Fisher Scientific is a global leader in serving science, supplying analytical instruments, laboratory equipment, life sciences reagents and consumables, specialty diagnostics, and software to research, clinical, and industrial laboratories worldwide. The company operates through four core segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services — the latter of which includes contract development and manufacturing for pharmaceutical and biotechnology companies through its PPD clinical research business. With a market capitalization of approximately $198 billion, TMO ranks among the largest healthcare and life sciences tools companies globally. Investors closely track the stock for its exposure to secular trends in biopharma R&D, diagnostics, and AI-enabled scientific workflows.

Thermo Fisher Scientific (TMO) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, TMO delivered a robust rally of approximately 14.6%, rising from a closing price of $464.61 on June 18, 2026, to $532.48 on July 17. The move was characterized by a steady upward grind punctuated by sharp breakout sessions — notably on June 24–26 and again in mid-July — reflecting renewed institutional accumulation and improving sentiment ahead of the company's second-quarter earnings report.

Zooming out to the full quarterly picture, TMO's trajectory tells a more complex story. The stock entered the quarter trading near $526 in mid-April, only to endure a punishing selloff following its Q1 earnings release on April 23. Despite beating consensus estimates with EPS of $5.44 and revenues of $11.01 billion, shares tumbled toward $466 as investors reacted to tariff-related concerns and broader macroeconomic uncertainty. The decline continued into mid-May, with TMO bottoming at $438.34 on May 15. From that trough, the stock staged a powerful recovery — gaining roughly 21.5% to reach current levels — resulting in a net quarterly gain of approximately 1.1%. The V-shaped recovery underscores both the depth of spring selling pressure and the conviction behind the subsequent rebound.

What Drove TMO Stock Price in the Last 30 Days

Several interconnected catalysts powered TMO's 30-day advance. First, a wave of institutional buying emerged through 13F filings, with firms such as Dimensional Fund Advisors, Allspring Global Investments, and Jag Capital Management all reporting increased or newly established positions. These disclosures reinforced the perception that sophisticated investors view the mid-May dip as a compelling entry point.

Second, anticipation around TMO's upcoming Q2 earnings release on July 23 has built steadily. The Zacks Consensus Estimate calls for EPS of $5.71 — a 6.5% year-over-year increase — on revenue of $11.68 billion. Positive pre-earnings commentary highlighting strength in the Bioproduction business, clinical research services, and newly integrated Clario digital endpoint solutions has contributed to the bullish tone.

Third, Thermo Fisher's strategic moves have resonated with the market. The agreement to sell its microbiology business to Astorg for approximately $1.075 billion signals portfolio optimization. Meanwhile, the company's collaboration with NVDA on AI-enabled scientific workflow solutions, the launch of the Glacios 3 Cryo-TEM with AI-powered workflows, and the unveiling of the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometry platforms at ASMS 2026 all underscore TMO's positioning at the intersection of life sciences and artificial intelligence. Additionally, Evercore initiated coverage with a $570 price target in early July, and Weiss Ratings upgraded the stock, while broader analyst sentiment stayed firmly in the Moderate Buy camp.

What Drove TMO Stock Performance Over the Last Quarter

The quarterly narrative is dominated by the sharp post-earnings selloff and the equally forceful recovery that followed. On April 23, TMO reported Q1 2026 results that topped Wall Street expectations — $5.44 in EPS versus the $5.25 consensus — and issued full-year 2026 EPS guidance of $24.64 to $25.12. Despite the beat, shares cratered roughly 9% in a single session as tariff headwinds, China demand softness in Analytical Instruments, and broader rotation out of healthcare names weighed heavily on sentiment. The selling extended through mid-May, when TMO touched a low of $438.34, marking a decline of approximately 17% from its mid-April levels.

The recovery, however, proved decisive. Bargain hunting by institutional investors, accelerating integration of the Clario acquisition, a series of high-profile product launches, and growing enthusiasm around AI-driven laboratory workflows coalesced into a sustained uptrend. By late May and early June, the stock had reclaimed the $480–$500 range, and momentum carried through into July, with TMO ultimately recouping nearly all of its post-earnings losses and pushing above $540 intraday before settling in the low $530s.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of top-performing AI-powered trading bots from a platform that features hundreds of bots actively trading thousands of tickers. These bots employ diverse strategies, timeframes, and performance metrics, and only the most relevant and consistently strong performers earn placement in this section. For traders and investors seeking to complement their own analysis with algorithm-driven insights, exploring the Trending AI Robots page can offer a practical window into how machine learning models are navigating current market conditions across multiple asset classes.

TMO Stock Forecast Drivers: What Investors Should Watch Next

The immediate catalyst on the horizon is Thermo Fisher's Q2 2026 earnings report on July 23. Investors will scrutinize revenue growth across all four segments — particularly Life Sciences Solutions and Laboratory Products and Biopharma Services — as well as any updates to full-year guidance. Progress on the Clario integration and the pending $1.075 billion microbiology divestiture to Astorg will also be in focus. On the macroeconomic front, U.S.-China trade dynamics and tariff policy remain potential headwinds for the Analytical Instruments segment. Additionally, the evolving AI partnership with NVIDIA and the commercial traction of newly launched platforms like the Orbitrap Tribrid Apex will serve as important bellwethers for TMO's innovation-driven growth narrative. While analyst consensus remains constructive, with price targets clustering between $520 and $639, the stock's ability to sustain its recent momentum will depend heavily on execution against these catalysts in the second half of 2026.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full Disclaimers and Limitations.